Design Therapeutics, Inc. (DSGN) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $3.14M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $3.14M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $3.14M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 13.27M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 3.14M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | (m) | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $2.66M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $3.14M | (m) | (m) | (m) | $13.27M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $2.28M | (m) | (m) | (m) | $12.39M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $2.31M | (m) | (m) | (m) | $13.70M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $1.91M | (m) | (m) | (m) | $12.05M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $1.01M | (m) | (m) | (m) | $9.85M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $3.18M | (m) | (m) | (m) | $9.56M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $2.19M | (m) | (m) | (m) | $10.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $1.47M | (m) | (m) | (m) | $9.18M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $1.30M | (m) | (m) | (m) | $8.34M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $1.37M | (m) | (m) | (m) | $9.24M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $1.94M | (m) | (m) | (m) | $11.96M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $2.21M | (m) | (m) | (m) | $14.91M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $1.92M | (m) | (m) | (m) | $14.84M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $2.74M | (m) | (m) | (m) | $11.93M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $3.02M | (m) | (m) | (m) | $13.83M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $2.62M | (m) | (m) | (m) | $13.63M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $2.07M | (m) | (m) | (m) | $10.77M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $1.90M | (m) | (m) | (m) | $8.49M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $1.62M | (m) | (m) | (m) | $8.43M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $2.22M | (m) | (m) | (m) | $8.79M | (m) | (m) | (m) | $11.00K | (m) |
| 2021-06-30 | (m) | $1.58M | (m) | (m) | (m) | $3.54M | (m) | (m) | (m) | $140.00K | (m) |
| 2021-03-31 | (m) | $2.03M | (m) | (m) | (m) | $3.85M | (m) | (m) | (m) | $142.00K | (m) |
| 2020-12-31 | (m) | $1.40M | (m) | (m) | (m) | $2.48M | (m) | (m) | (m) | $145.00K | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |